[Changes in vitamin B2 and changes in the liver function in various diseases].

Y Hashigami; J Fujino; K Suzuki; T Higuchi; S Ikegami

Home/Archive/PubMed

PubMed · 6056299

[Changes in vitamin B2 and changes in the liver function in various diseases].

Y Hashigami·J Fujino·K Suzuki·T Higuchi·S Ikegami

View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Gastrointestinal Diseases Hepatitis B Liver Function Tests Riboflavin Tuberculosis, Pulmonary Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Y Hashigami, J Fujino, K Suzuki, T Higuchi, S Ikegami. 1967. [Changes in vitamin B2 and changes in the liver function in various diseases].. https://pubmed.ncbi.nlm.nih.gov/6056299/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

[Symptoms involving the gastrointestinal tract].

Symptoms involving the gastrointestinal tract are very common in patients who require palliative treatment. They can be caused by the patient's underlying (malignant) disease or by the treatment of this disease. Nausea and vomiting as well as constipation are of the utmost importance in this context due both to their frequency as well as their complex consequences. A careful evaluation of the patient's history combined with a few diagnostic procedures will help to provide a treatment which is orientated on pathophysiology.

Gastrointestinal Diseases↗

PubMed2006

Thymidine phosphorylase gene mutations cause mitochondrial neurogastrointestinal encephalomyopathy (MNGIE).

Explore the source record for details and available documents.

Gastrointestinal Diseases↗

PubMed2006

Serotonergic receptors in therapeutic approaches to gastrointestinal disorders.

Most of the cloned serotonin (5-HT) receptor subtypes are present on enteric neurons that control gastrointestinal function. Because of the wide distribution of 5-HT receptor subtypes in the gut, the precise actions of currently marketed drugs are unclear. Furthermore, efficacy of these drugs varies between individuals. Two recent advances provide important potential explanations for this phenomenon: polymorphisms have recently been discovered in the gene for the key enzyme in neural 5-HT production, and physiologically relevant 5-HT(4) receptor splice variants have been shown to be differentially located across intestinal regions. Functional 5-HT(7) receptors have recently been demonstrated in the gut and, together with the 5-HT(1A) receptor, offer new therapeutic options. In addition, recently suggested identities for the elusive 5-HT(1P) receptor could result in other, more effective therapeutic targets.

Gastrointestinal Diseases↗